Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients

The impact of distinct disease‐modifying therapies (DMTs) on severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune‐responses in...

Descripción completa

Detalles Bibliográficos
Autores principales: Trümpelmann, Susan, Schulte‐Mecklenbeck, Andreas, Steinberg, Olga V., Wirth, Timo, Fobker, Manfred, Lohmann, Lisa, Lünemann, Jan D., Wiendl, Heinz, Gross, Catharina C., Klotz, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111759/
https://www.ncbi.nlm.nih.gov/pubmed/35213793
http://dx.doi.org/10.1111/cts.13256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111759/
https://www.ncbi.nlm.nih.gov/pubmed/35213793
http://dx.doi.org/10.1111/cts.13256

Ejemplares similares